In coming weeks, Agendia, probably best known for its genetic breast cancer test, hopes to complete an initial public offering (IPO). Agendia is a company based in Amsterdam, The Netherlands with offices in Irvine, California. Its stock symbol will be “AGDX” and the shares will trade on the Euronext Amsterdam exchange. Plans are to raise […]
To access this post, you must purchase The Dark Report.